In conclusion, these results show that PP2A is a synthetic lethal target for BRCA2-deficient tumor cells, and the PP2Ais reduce potential drug resistance to PARPis and enhance their therapeutic effect. This evidence concerns the gene BRCA2 and neoplasm.